NasdaqGS - Delayed Quote • USD
Apellis Pharmaceuticals, Inc. (APLS)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:59 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
396,591.00
396,591.00
75,422.00
66,563.00
250,646.00
Cost of Revenue
58,510.00
58,510.00
5,636.00
5,200.00
25,050.00
Gross Profit
338,081.00
338,081.00
69,786.00
61,363.00
225,596.00
Operating Expense
855,202.00
855,202.00
664,399.00
597,640.00
439,322.00
Operating Income
-517,121.00
-517,121.00
-594,613.00
-536,277.00
-213,726.00
Net Non Operating Interest Income Expense
-8,648.00
-8,648.00
-23,712.00
-12,823.00
-25,773.00
Other Income Expense
-727.00
-727.00
-33,178.00
-196,902.00
-103,530.00
Pretax Income
-526,496.00
-526,496.00
-651,503.00
-746,002.00
-343,029.00
Tax Provision
2,132.00
2,132.00
669.00
352.00
1,845.00
Net Income Common Stockholders
-528,628.00
-528,628.00
-652,172.00
-746,354.00
-344,874.00
Diluted NI Available to Com Stockholders
-528,628.00
-528,628.00
-652,172.00
-746,354.00
-344,874.00
Basic EPS
-5.23
-4.45
-6.15
-8.84
-4.59
Diluted EPS
-5.23
-4.45
-6.15
-8.84
-4.59
Basic Average Shares
116,028.25
118,678.00
106,114.00
84,421.00
75,163.00
Diluted Average Shares
116,028.25
118,678.00
106,114.00
84,421.00
75,163.00
Total Operating Income as Reported
-517,121.00
-517,121.00
-594,613.00
-536,277.00
-213,726.00
Total Expenses
913,712.00
913,712.00
670,035.00
602,840.00
464,372.00
Net Income from Continuing & Discontinued Operation
-528,628.00
-528,628.00
-652,172.00
-746,354.00
-344,874.00
Normalized Income
-528,628.00
-528,628.00
-626,188.90
-601,621.28
-269,662.83
Interest Income
20,933.00
20,933.00
8,914.00
418.00
4,164.00
Interest Expense
29,581.00
29,581.00
32,626.00
13,241.00
29,937.00
Net Interest Income
-8,648.00
-8,648.00
-23,712.00
-12,823.00
-25,773.00
EBIT
-496,915.00
-496,915.00
-618,877.00
-732,761.00
-313,092.00
EBITDA
-495,211.00
-495,211.00
-617,390.00
-731,269.00
-312,233.00
Reconciled Cost of Revenue
58,510.00
58,510.00
5,636.00
5,200.00
25,050.00
Reconciled Depreciation
1,704.00
1,704.00
1,487.00
1,492.00
859.00
Net Income from Continuing Operation Net Minority Interest
-528,628.00
-528,628.00
-652,172.00
-746,354.00
-344,874.00
Total Unusual Items Excluding Goodwill
--
--
-32,890.00
-198,264.00
-103,029.00
Total Unusual Items
--
--
-32,890.00
-198,264.00
-103,029.00
Normalized EBITDA
-495,211.00
-495,211.00
-584,500.00
-533,005.00
-209,204.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
--
--
-6,906.90
-53,531.28
-27,817.83
12/31/2020 - 11/9/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BBIO BridgeBio Pharma, Inc.
24.88
+2.26%
CYTK Cytokinetics, Incorporated
65.34
+0.83%
DAWN Day One Biopharmaceuticals, Inc.
14.92
+12.94%
BPMC Blueprint Medicines Corporation
93.00
+2.50%
MDGL Madrigal Pharmaceuticals, Inc.
193.33
-0.54%
LEGN Legend Biotech Corporation
45.30
+1.98%
ALNY Alnylam Pharmaceuticals, Inc.
143.31
-0.28%
IMVT Immunovant, Inc.
27.17
-2.09%
BMRN BioMarin Pharmaceutical Inc.
80.91
-1.53%
BHVN Biohaven Ltd.
38.97
+1.12%